Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.49 |
| ▸ | BRAF | P15056 | 9/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.45 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.45 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.45 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.45 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.44 |
| ▸ | RAF1 | P04049 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5440513 | 0.91 | EGFR (0.46) | EGFRBRAFERBB2ERBB4TGFBR1 | |
| SCHEMBL5437478 | 0.90 | ABCG2 (0.48) | EGFRBRAFERBB2ERBB4TGFBR1 | |
| SCHEMBL4508756 | 0.90 | EGFR (0.59) | EGFRERBB2ERBB4TGFBR1GRM4 | |
| SCHEMBL5440546 | 0.86 | EGFR (0.45) | EGFRBRAFERBB2ERBB4TGFBR1 | |
| SCHEMBL5446058 | 0.86 | EGFR (0.45) | EGFRBRAFERBB2ERBB4TGFBR1 | |
| SCHEMBL5446070 | 0.83 | TGFBR1 (0.46) | EGFRERBB2ERBB4TGFBR1GRM4 | |
| SCHEMBL5452047 | 0.82 | EGFR (0.43) | EGFRBRAFERBB2ERBB4TGFBR1 | |
| SCHEMBL5445026 | 0.82 | EGFR (0.45) | EGFRERBB2ERBB4TGFBR1GRM4 | |
| SCHEMBL5440959 | 0.81 | EGFR (0.47) | EGFRERBB2ERBB4TGFBR1GRM4 | |
| SCHEMBL4505968 | 0.80 | EGFR (0.54) | EGFRERBB2ERBB4TGFBR1GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007511570-A | — | — | 2007-05-10 | — | — | JP | claimed |
| US-20070072901-A1 | 1-Amino-isoquinoline derivatives for the treatment of diseases associated with inappropriate alk5 | GLAXO GROUP LIMITED (GB) | 2007-03-29 | — | — | US | claimed |
| EP-1689718-A1 | 1-AMINO-ISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH INAPPROPRIATE ALK5 ACTIVITY | GLAXO GROUP LIMITED (GB) | 2006-08-16 | — | — | EP | claimed |
| WO-2005049577-A1 | 1-AMINO-ISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH INAPPROPRIATE ALK5 | GLAXO GROUP LIMITED (GB) | 2005-06-02 | — | — | WO | claimed |
| US-20070072901-A1 | 1-Amino-isoquinoline derivatives for the treatment of diseases associated with inappropriate alk5 | GLAXO GROUP LIMITED (GB) | 2007-03-29 | — | — | US | disclosed |
| US-20070072901-A1 | 1-Amino-isoquinoline derivatives for the treatment of diseases associated with inappropriate alk5 | GLAXO GROUP LIMITED (GB) | 2007-03-29 | — | — | US | disclosed |
| US-20070072901-A1 | 1-Amino-isoquinoline derivatives for the treatment of diseases associated with inappropriate alk5 | GLAXO GROUP LIMITED (GB) | 2007-03-29 | — | — | US | disclosed |
| EP-1689718-A1 | 1-AMINO-ISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH INAPPROPRIATE ALK5 ACTIVITY | GLAXO GROUP LIMITED (GB) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005049577-A1 | 1-AMINO-ISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH INAPPROPRIATE ALK5 | GLAXO GROUP LIMITED (GB) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072901-A1 | 1-Amino-isoquinoline derivatives for the treatment of diseases associated with inappropriate alk5 | ALK, NPR3, CBR3 | EGFR 1404/4885BRAF 1718/4885ERBB2 1046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.